Siemens Healthcare Diagnostics Products Gmbh

Dade Behring Marburg Gmbh

Sysmex Corporation

Behringwerke Aktiengesellschaft

Behringwerke Diagnostics Gmbh

Norbert F Zander

Harald Althaus

Karl Fickenscher

Herbert Schwarz

Andreas Rechner

Andreas Kappel

Gerlinde Christ

Sabine Pilgrim

Carsten Schelp

Takayoshi Izumi

Konrad Braun

Susumu Hoshiko

Yoshihiro Mishima

Frank Vitzthum

Thomas Wissel

Stefan Teigelkamp

Masayuki Katayama

Leszek Wieczorek

Andrea Lichte

Dirk Greis

Wilfried Meyers

Michaela Wicke

Wolfgang Klein

Michael Timme

Sabine Teigelkamp, Legal Representative

Joerg Endermann

Matthias Wilkens

Lena Pechmann

Frank Vitzhum

The present invention pertains to the field of coagulation diagnostics and relates to a prothrombin time reagent on the basis of recombinant or native tissue factor protein and phospholipids, which reagent can be stabilized by the addition of an iron chelator from the groups of siderophores and 3,5-diphenyl-1,2,4-triazoles.

Iron chelator-containing prothrombin time reagent

The present disclosure is in the field of in vitro diagnostics and relates to an easily automatable binding assay for establishing a heparin-induced thrombocytopenia, which binding assay uses Fc&#x3b3;RIIa protein-coated particles.

Binding assay for the diagnosis of a heparin-induced thrombocytopenia

The present invention relates to a functional, easily automatable assay for establishing a heparin-induced thrombocytopenia (HIT). What is measured is the secretion of PF4 (platelet factor 4) from activated thrombocytes.

Activation assay for the diagnosis of a heparin-induced thrombocytopenia

The invention relates to the field of blood clotting diagnosis and relates to a kinetic method for determining the fibrinogen concentration in a human plasma sample according to the Clauss method.

Method for determining fibrinogen and automatic analyzer

The present invention relates to a chromogenic method for simultaneously determining the activity of multiple coagulation proteases or for simultaneously determining the inhibition of multiple coagulation proteases in a single test reaction. For this purpose, use is made of two chromogenic substrates which have different absorption maxima and whose color signals can be separated spectrally.

Method for simultaneously determining multiple coagulation proteases

The invention lies in the field of platelet function diagnostics and relates to devices and methods for determining the platelet function in a centrifugal analyzer.

Devices for determining the platelet function in a centrifugal analyzer

The present invention is in the field of in-vitro diagnostics and relates to a method of determining the blood-clotting factor XIII (factor XIII, F XIII) with the aid of plasma-based reference material, and a test kit for carrying out the method.

Method of determining factor XIII with the aid of plasma-based reference material

The present invention is in the field of coagulation diagnostics and relates to a kit and method for preparing controls for use in test methods for determining thrombocyte function.

Controls and kit for thrombocyte activity tests

The invention is in the field of coagulation diagnostics and relates to a heparin-insensitive method for determining direct coagulation factor inhibitors in a sample, in particular direct thrombin and factor Xa inhibitors.

Heparin-insensitive method for determining direct coagulation factor inhibitors

The invention relates to methods for determining the activity of a proteolytic coagulation factor of the blood coagulation cascade in a body fluid such as whole blood or plasma. A combination is provided in a reaction mixture. The combination comprises the sample and an activation agent for activating a proteolytic coagulation factor of the blood coagulation cascade or for activating the blood coagulation cascade. The effect of the activating on a reagent system comprising a cleavable moiety is evaluated. The cleavable moiety is or becomes bound to a chemiluminescent agent or a sensitizer agent or both. The chemiluminescent agent and the sensitizer agent are related in that, when in close proximity, energization of the sensitizer agent results in energization of the chemiluminescent agent. The effect of the activating is related to the activity of a proteolytic coagulation factor of the blood coagulation cascade wherein the effect is the extent of cleavage of the cleavable moiety.

Blood coagulation assays

The invention is in the field of coagulation diagnosis and relates to a liquid, buffer-based D-dimer composition, which additionally contains fibrinogen and which is suitable as a standard material for control or calibration purposes for D-dimer test procedures.

Stable D-dimer liquid preparation

The present invention lies in the field of coagulation diagnosis and relates to a procedure for the standardization of coagulation tests, where calibrators are used to which a discrete standard coagulation time is assigned. The procedure is particularly suitable for the standardization of prothrombin time, activated partial thromboplastin time, thrombin time, ecarin time or batroxobin time.

Procedure for the standardization of coagulation tests

An analyzing method of a blood coagulation reaction by detecting an optical change of a blood sample with an elapse of time, the method includes: setting at least one checkpoint or check region between a starting point of the blood coagulation reaction and the endpoint thereof; and monitoring a reaction state of the blood coagulation reaction at the checkpoint or in the check region to detect an abnormality of the blood coagulation reaction.

Analyzing method of a blood coagulation reaction

The present invention relates to a process for preparing functional recombinant tissue factor in a prokaryotic host organism.

Growing community of inventors

Marburg, Germany

Norbert F Zander